Patients with Multiple Sclerosis treated with Fingolimod: Real World UK Experience (MSFine)
Phase of Trial: Phase IV
Latest Information Update: 16 Jun 2016
At a glance
- Drugs Fingolimod (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms MSFine
- Sponsors Novartis
- 17 May 2016 Status changed from recruiting to completed.
- 14 Apr 2015 Planned number of patients changed from 210 to 300 as reported by United Kingdom Clinical Research Network record.
- 08 Jan 2015 New trial record